Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) – Pipeline Review, H2 2016’, provides in depth analysis on Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted pipeline therapeutics.

The report provides comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)

The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics and enlists all their major and minor projects

The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc.

AstraZeneca Plc

Bayer AG

Curis, Inc.

GlaxoSmithKline Plc

Hutchison MediPharma Limited

Karus Therapeutics Limited

Novartis AG

PIQUR Therapeutics AG

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) Overview 8

Therapeutics Development 9

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) - Products under Development by Stage of Development 9

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) - Products under Development by Therapy Area 10

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) - Products under Development by Indication 11

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) - Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) - Products under Development by Companies 15

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) - Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 23

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) - Companies Involved in Therapeutics Development 24

Amgen Inc. 24

AstraZeneca Plc 25

Bayer AG 26

Curis, Inc. 27

GlaxoSmithKline Plc 28

Hutchison MediPharma Limited 29

Karus Therapeutics Limited 30

Novartis AG 31

PIQUR Therapeutics AG 33

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) - Drug Profiles 34

AZD-8186 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

BAY-1082439 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

buparlisib hydrochloride - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CUDC-907 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

GSK-2636771 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

HM-032 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

KA-1463 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

KA-2237 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

KAR-4000 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

PQR-309 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecule to Inhibit PI3K Beta for Bleeding and Clotting Disorders - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule to Inhibit PI3K Beta/Delta for Rheumatoid Arthritis - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecule to Inhibit PI3K for Prostate Cancer - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

SRX-2523 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) - Dormant Projects 59

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) - Discontinued Products 62

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC

2.7.1.153) - Featured News & Press Releases 63

Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 63

Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 63

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 63

Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 64

Jan 11, 2016: Seahorse Bioscience XF Technology Reaches 500th Citation in Cancer Research 64

Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 65

Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting 67

Jun 10, 2015: Curis to Present CUDC-907 Clinical Data at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma 67

May 31, 2015: Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting 68

May 27, 2015: PIQUR announces positive Phase 1 study results and the start of Phase 2 of PQR309 69

May 20, 2015: Curis Announces Presentations of CUDC-907 Clinical Data at 2015 ASCO Annual Meeting 70

Apr 21, 2015: SignalRx Presents at 10th Annual Drug Discovery Chemistry Conference on its Dual Kinase-Epigenetic Inhibitors for Treating Cancer 71

Apr 17, 2015: PIQUR to present posters on its lead compound PQR309 at AACR Annual Meeting 2015 71

Apr 06, 2015: Curis Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma 72

Dec 18, 2014: Curis Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients With Advanced/ Relapsed Solid Tumors 73

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Products under Development by Companies, H2 2016 (Contd..2) 18

Products under Development by Companies, H2 2016 (Contd..3) 19

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by Amgen Inc., H2 2016 24

Pipeline by AstraZeneca Plc, H2 2016 25

Pipeline by Bayer AG, H2 2016 26

Pipeline by Curis, Inc., H2 2016 27

Pipeline by GlaxoSmithKline Plc, H2 2016 28

Pipeline by Hutchison MediPharma Limited, H2 2016 29

Pipeline by Karus Therapeutics Limited, H2 2016 30

Pipeline by Novartis AG, H2 2016 31

Pipeline by PIQUR Therapeutics AG, H2 2016 33

Dormant Projects, H2 2016 59

Dormant Projects (Contd..1), H2 2016 60

Dormant Projects (Contd..2), H2 2016 61

Discontinued Products, H2 2016 62

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports